These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 17580150)

  • 21. Conversion from cyclosporin A to sirolimus retards the progression of chronic allograft nephropathy in the long term in a rat kidney transplantation model.
    He Z; Chen L; Qiu J; Li J; Zhao D; Chen G; Wang C
    J Int Med Res; 2009; 37(5):1396-410. PubMed ID: 19930844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure.
    Johnson RW; Kreis H; Oberbauer R; Brattström C; Claesson K; Eris J
    Transplantation; 2001 Sep; 72(5):777-86. PubMed ID: 11571437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K
    Transplantation; 2003 Apr; 75(8):1404-8. PubMed ID: 12717239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
    Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
    Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of rapamycin versus FK506 on expression of cytoprotective genes in the rat kidney allografts undergoing chronic allograft nephropathy.
    Teng D; Lu Y; Gao R; Xin Y; Cao G; Li X; Wang L; Wang J; Li Y
    Transplant Proc; 2006 Sep; 38(7):2172-5. PubMed ID: 16980034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sirolimus rescue therapy for refractory rejection in renal transplantation.
    Hong JC; Kahan BD
    Transplantation; 2001 Jun; 71(11):1579-84. PubMed ID: 11435968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy.
    Bakker RC; Hollander AA; Mallat MJ; Bruijn JA; Paul LC; de Fijter JW
    Kidney Int; 2003 Sep; 64(3):1027-34. PubMed ID: 12911553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful reversal of acute vascular rejection and cyclosporine-associated nephrotoxicity in renal allograft with combined sirolimus and mycophenolate mofetil as immunotherapy.
    Ołdakowska-Jedynak U; Paczek L; Mucha K; Foroncewicz B; Perkowska-Ptasińska A
    Transplant Proc; 2006; 38(1):66-8. PubMed ID: 16504666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients.
    Boratyńska M; Banasik M; Watorek E; Falkiewicz K; Patrzałek D; Szyber P; Klinger M
    Transplant Proc; 2006; 38(1):101-4. PubMed ID: 16504675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in de novo renal allograft patients receiving sirolimus.
    Tedesco-Silva H; Garcia VD; Contieri FL; De Boni Monteiro de Carvalho D; Noronha IL; Gonçalves RT; de Paula FJ; Abbud-Filho M; Manfro RC; David-Neto E; Alfieri F; Ikehara E; Jiang Q; Tai SS; Medina-Pestana JO
    Transplant Proc; 2010 Jun; 42(5):1659-66. PubMed ID: 20620495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. De novo sirolimus-based regimen in Thai renal transplant recipients.
    Townamchai N; Avihingsanon Y; Praditpornsilpa K; Tungsanga K; Eiam-Ong S
    Transplant Proc; 2008 Sep; 40(7):2206-8. PubMed ID: 18790193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
    Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function.
    Russ G; Segoloni G; Oberbauer R; Legendre C; Mota A; Eris J; Grinyó JM; Friend P; Lawen J; Hartmann A; Schena FP; Lelong M; Burke JT; Neylan JF;
    Transplantation; 2005 Nov; 80(9):1204-11. PubMed ID: 16314787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients.
    Stallone G; Di Paolo S; Schena A; Infante B; Grandaliano G; Battaglia M; Gesualdo L; Schena FP
    Transplantation; 2003 Apr; 75(7):998-1003. PubMed ID: 12698087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sirolimus attenuates chronic allograft nephropathy in an experimental rat kidney transplantation model.
    Savikko J; von Willebrand E
    Transplant Proc; 2006 Oct; 38(8):2699-700. PubMed ID: 17098043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
    Morales JM; Campistol JM; Kreis H; Mourad G; Eris J; Schena FP; Grinyo JM; Nanni G; Andres A; Castaing N; Brault Y; Burke JT
    Transplant Proc; 2005 Mar; 37(2):693-6. PubMed ID: 15848504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions.
    Ruiz JC; Campistol JM; Grinyó JM; Mota A; Prats D; Gutiérrez JA; Henriques AC; Pinto JR; García J; Morales JM; Gómez JM; Arias M
    Transplantation; 2004 Nov; 78(9):1312-8. PubMed ID: 15548969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial.
    Salvadori M; Scolari MP; Bertoni E; Citterio F; Rigotti P; Cossu M; Dal Canton A; Tisone G; Albertazzi A; Pisani F; Gubbiotti G; Piredda G; Busnach G; Sparacino V; Goepel V; Messa P; Berloco P; Montanaro D; Veroux P; Federico S; Bartezaghi M; Corbetta G; Ponticelli C
    Transplantation; 2009 Nov; 88(10):1194-202. PubMed ID: 19935373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential therapeutic interventions to avoid or treat chronic allograft dysfunction.
    Kahan BD
    Transplantation; 2001 Jun; 71(11 Suppl):SS52-7. PubMed ID: 11583490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conversion to sirolimus allows preservation of renal function in kidney and kidney-pancreas allograft recipients.
    Laham G; Sleiman S; Soler Pujol G; Diaz C; Dávalos M; Vilches A
    Transplant Proc; 2010; 42(1):309-13. PubMed ID: 20172338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.